1492 Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

1492 Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-62,397	Closed	-$7.17M	–	159
2014 Q4	$7.17M	Sell	62,397 -7,770	-11%	-$941K	4.49%	1
2014 Q3	$11M	Sell	70,167 -5,596	-7%	-$811K	6.07%	1
2014 Q2	$9.35M	Sell	75,763 -1,050	-1%	-$116K	4.8%	1
2014 Q1	$7.96M	Buy	76,813 +5,117	+7%	+$524K	3.95%	1
2013 Q4	$6.45M	Buy	+71,696	New	+$5.72M	3.47%	2

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1492 Capital Management's SLXP Position: Q1 2015 in Review

1492 Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 62,397 shares — an estimated $7.17M sold.

1492 Capital Management first reported a position in SLXP in Q4 2013 and held it in 5 quarters. The position peaked at $11M in Q3 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

1492 Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
1492 Capital Management sold 62,397 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $7.17M.
1492 Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2013 and held it in 5 quarters.
1492 Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $11M in Q3 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on 1492 Capital Management's 13F filing for Q1 2015, filed 13 May 2015.